✦ LIBER ✦

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

✍ Scribed by E. Claire Dees; Bert H. O’Neil; Celeste M. Lindley; Frances Collichio; Lisa A. Carey; Jason Collins; William J. Riordan; Anastasia Ivanova; Dixie Esseltine; Robert Z. Orlowski

Publisher: Springer
Year: 2008
Tongue: English
Weight: 527 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0716-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

A phase I and pharmacologic study of the

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

✍ A. S. T. Planting; P. Sonneveld; A. van der Gaast; A. Sparreboom; M. E. L. van d 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 253 KB

Extended follow-up of outcome measures i

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

✍ Suzanne E. Biehn; Dominic T. Moore; Peter M. Voorhees; Reynaldo A. Garcia; Mary 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 128 KB

A phase I study of Triapine®in combinati

A phase I study of Triapine®in combination with doxorubicin in patients with advanced solid tumors

✍ William R. Schelman; Sherry Morgan-Meadows; Rebecca Marnocha; Fred Lee; Jens Eic 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 364 KB

A phase I study of bortezomib and temozo

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

✍ J. Portnow; P. Frankel; S. Koehler; P. Twardowski; S. Shibata; C. Martel; R. Mor 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 384 KB

Phase I dose and sequencing study of peg

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad